AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A composition comprising a cetylated ~~an esterified~~ fatty acid.

2. – 7. (Canceled)

8. (Currently Amended) The composition of claim 1, wherein the cetylated ~~esterified~~ fatty acid is about 70% to about 80% of the composition.

9. (Currently Amended) The composition of claim 1, wherein the cetylated ~~esterified~~ fatty acid is about 70% to about 75% of the composition.

10. (Currently Amended) The composition of claim 1, wherein the cetylated ~~esterified~~ fatty acid is about 74% of the composition.

11. – 15. (Canceled)

16. (Currently Amended) The composition of claim 1, wherein the cetylated ~~esterified~~ fatty acid is selected from the group consisting of decanoic acid, lauric acid, myristoleic acid, myristic acid, palmitoleic acid, palmitic acid, oleic acid and stearic acid and mixtures thereof.

17. (Currently Amended) A pharmaceutical composition for treating an arthritis[[,]] or periodontal disease, ~~psoriasis or cardiovascular condition~~ comprising about 70% to about 80% of an cetylated ~~esterified~~ fatty acid and pharmaceutically acceptable carriers thereof.

18. (Original) The pharmaceutical composition of claim 17, wherein the pharmaceutical composition further comprises biocompatable polymers as protective colloids, suspensions or bulking agents, excipients, binders and carriers.

19. (Currently Amended) A method of treating an arthritis[[,]] or periodontal disease~~, psoriasis, or heart or cardiovascular condition~~ comprising administering an effective amount of the composition of claim 1 to a subject in need of such treatment.

20. (Canceled)

21. (Original) The method of claim 19, wherein the subject is a mammal.

22. (Original) The method of claim 21, wherein the mammal is human.

23. (Original) The method of claim 21, wherein the mammal is canine or feline.

24. (Original) The method of claim 19, wherein the composition is administered via topical application.

25. (Original) The method of claim 24, wherein the amount of the composition administered is about 1 to 15 mg/kg of body weight of said subject per day.

26. (Original) The method of claim 24, wherein the amount of the composition administered is about 3 to 10 mg/kg of body weight of said subject per day.

27. (Original) The method of claim 24, wherein the amount of the composition administered is about 5 to 8 mg/kg of body weight of said subject per day.

28. (Original) The method of claim 19, wherein the composition is administered orally.

29. (Original) The method of claim 28, wherein the amount of the composition administered is about 5 to 32 mg/kg of body weight of said subject per day.

30. (Original) The method of claim 28, wherein the amount of the composition administered is about 10 to 30 mg/kg of body weight of said subject per day.

31. (Original) The method of claim 28, wherein the amount of the composition administered is about 15 to 25 mg/kg of body weight of said subject per day.

32. (Original) The method of claim 28, wherein the composition is administered via a soft gel.

33. (Original) The method of claim 19, wherein the composition is administered once a day.

34. (Original) The method of claim 19, wherein the composition is administered twice a day.

35. (Currently Amended) The method of claim 19, wherein the composition is administered to a subject in combination with another compound or therapy effective to treat arthritis[[,]] or periodontal disease~~, psoriasis, or a cardiovascular or heart disease~~.

36. (Previously Presented) The pharmaceutical composition of claim 18, wherein the biocompatable polymers are selected from the group consisting of lecithin fatty acids, olive oil fatty acids, and tocophenols.